A Gene Editing Breakthrough
By Tom Ashbrook,
NPR On Point [features Marcy Darnovsky]
| 08. 08. 2017
After the blockbuster announcement a U.S. team successfully edited human embryos come the tough medical and ethical questions. We’ll talk it through.
A first in the U.S.: researchers have now edited the genetic code of viable human embryos, cutting and splicing to avoid defect and disease. The DNA of human embryos. Genetically edited. The edited embryos weren’t implanted in a woman. Weren’t born. But they could have been. New life spared disease, maybe death. How far does this gene editing go? How fast? For whom? And for, or against, what human traits? This hour On Point: editing the code of human life. -- Tom Ashbrook
Guests
Amy Dockser Marcus, health and science reporter for the Wall Street Journal. (@AmyDMarcus)
Dr. Paula Amato, co-author of the study showing successful editing of genes in human embryos. Associate professor of obstetrics and gynecology at Oregon Health & Science University.
Arthur Caplan, professor of bioethics and head of the division of medical ethics at the New York University School of Medicine. (@ArthurCaplan)
Marcy Darnovsky, executive director of...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...